Letting cancer patients choose their Quit-Smoking method may boost success

NCT ID NCT04634071

Completed Disease control Sponsor: Joseph Valentino, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether letting cancer patients choose their own smoking cessation treatment helps them quit. 126 patients with tobacco-related cancers received either varenicline, bupropion, or nicotine patches based on their preference, plus counseling. The goal was to see if personalized choice improves quit rates compared to randomly assigned treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Varenicline, Bupropion, or nicotine patches
What this could lead to: If successful, this could show that letting cancer patients choose their own smoking cessation method helps them quit more effectively, potentially improving cancer treatment outcomes.
What could go wrong: This is a Phase 2 trial with only 126 participants, so results may not apply to all patients. Quitting smoking is difficult, and the study compares preferences, not a new drug, so the impact may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER, TREATMENT-RELATED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behavior, Addictive Neoplasms, Second Primary secondary malignant neoplasm Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER, TREATMENT-RELATED SMOKING CESSATION

Contacts and locations

Locations

Med Center Health

Bowling Green, Kentucky, 42101, United States
Owensboro Health Mitchell Memorial Cancer Center

Owensboro, Kentucky, 42303, United States
University Of Kentucky, Markey Cancer Center

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.